441 filings
Page 15 of 23
8-K
x7r1ciar w3ht
4 Mar 16
Entry into a Material Definitive Agreement
12:00am
8-K
0m81cnefqkk
25 Feb 16
Regulation FD Disclosure
12:00am
8-K
n3bmrxh
19 Feb 16
Departure of Directors or Certain Officers
12:00am
8-K
uno 57630v9p
17 Feb 16
Departure of Directors or Certain Officers
12:00am
8-K
77tjogc vyyyyrkw7
11 Jan 16
Results of Operations and Financial Condition
12:00am
8-K
vlliqw0f 3gt18g028
8 Jan 16
AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study(IAP312)for Zalviso™ in 1Q 2016
12:00am
8-K
xhipxi9n 3b
14 Dec 15
AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04
12:00am
CT ORDER
2jkcs 99w4ieax0
8 Dec 15
Confidential treatment order
12:00am
CT ORDER
uxdmg phql0rzo
13 Nov 15
Confidential treatment order
12:00am
8-K
orh7h
2 Nov 15
Other Events
12:00am
8-K
1wbznojgokvk6w
29 Oct 15
AcelRx Pharmaceuticals Provides Business Update and Reports Third Quarter and Nine Months 2015 Financial Results
12:00am
8-K
zekpbwi01cn6
8 Oct 15
AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso
12:00am
8-K
n1mj2n8
2 Oct 15
Regulation FD Disclosure
12:00am
8-K
mmbj0ayrj 1ypv
22 Sep 15
Approval triggers $15 million milestone payment to AcelRx from Grunenthal
12:00am
8-K
behclsppfvsdbmog
21 Sep 15
Entry into a Material Definitive Agreement
12:00am
8-K
ontu1
9 Sep 15
Other Events
12:00am
8-K
p2to vdifu
8 Sep 15
Regulation FD Disclosure
12:00am
8-K
hb5df0510xmgm23q
21 Aug 15
Changes in Registrant's Certifying Accountant
12:00am
8-K
eqt08lqywfp pqn
4 Aug 15
Timothy Morris; AcelRx Pharmaceuticals, Inc.; CFO & Head of Business Development
12:00am